COMMUNIQUÉS West-GlobeNewswire

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
24/10/2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases ORR and median duration of [...]
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
24/10/2026
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or [...]
KFSH élargit l’accès aux urgences grâce aux soins virtuels et à la coordination des spécialistes
24/10/2026
RIYAD, Arabie saoudite, 24 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSH) élargit l’accès des patients à l’expertise des services d’urgence au-delà de ses locaux. Son accès [...]
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
24/10/2026
RIYADH, Saudi Arabia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is widening patients’ access to emergency expertise beyond its physical departments. Its virtual [...]
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
24/10/2026
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels Confirmed objective response rates (cORR) of [...]
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
24/10/2026
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate [...]
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
24/10/2026
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence Interim analysis [...]
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
24/10/2026
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
24/10/2026
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight’s [...]
Beyond Elizabeth Holmes: Ryan El Hosseiny Thanks Nathan Fielder for Shining a Light on Cancer Research
23/10/2026
MIAMI, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Featured as “The Billboard Guy” in Nathan Fielder's documentary, You Can See Everything , biochemist, entrepreneur and Just Blood founder Ryan El Hosseiny welcomes the spotlight [...]
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
23/10/2026
First-in-human data for ARR-217 selected as a late-breaking oral presentation ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., [...]
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
23/10/2026
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity [...]
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
23/10/2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the [...]
The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026
23/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
J-Star Holding Co., Ltd. Files Interim Financial Report on Form 6-K
23/10/2026
Company is Highlighting Strategic Focus on U.S. Opportunities, Balance Sheet Improvement, and Management Commitment TAICHUNG, Taiwan and HOUSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT [...]
Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs
23/10/2026
Cette collaboration vise à améliorer la planification des essais cliniques et à élargir l’accès des patients aux études ciblées par biomarqueurs en Australie Points clés Cette collaboration vise à accélérer la recherche [...]
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
23/10/2026
Price barriers are falling, as improving technicals meet a string of clinical, international, and regulatory milestones with November 17’s FDA meeting next on the calendar. DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- ( [...]
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
23/10/2026
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient [...]
Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaire
23/10/2026
Sous réserve de son approbation, l’association TALVEY ® et daratumumab constituerait la seule association thérapeutique comprenant un anticorps bispécifique ciblant le GPRC5D dans le traitement du myélome multiple en [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum